艾德生物
(300685)
| 流通市值：67.87亿 | | | 总市值：67.96亿 |
| 流通股本：3.90亿 | | | 总股本：3.90亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 559,346,697.42 | 260,346,165.81 | 1,197,733,641.14 | 865,632,981.04 |
| 营业收入 | 559,346,697.42 | 260,346,165.81 | 1,197,733,641.14 | 865,632,981.04 |
| 二、营业总成本 | 374,220,703.18 | 168,270,302.9 | 784,423,277.66 | 560,748,986.69 |
| 营业成本 | 92,800,836.11 | 45,667,093.85 | 208,514,045.82 | 140,719,994.31 |
| 税金及附加 | 6,620,382.64 | 3,005,448.24 | 13,178,447.19 | 9,925,326.97 |
| 销售费用 | 129,365,112.29 | 51,518,969.78 | 334,051,443.03 | 245,482,654.2 |
| 管理费用 | 33,107,935.2 | 16,271,994.26 | 72,915,023.15 | 57,368,980.67 |
| 研发费用 | 91,174,528.03 | 44,405,358.73 | 177,587,376.66 | 132,378,739.86 |
| 财务费用 | 21,151,908.91 | 7,401,438.04 | -21,823,058.19 | -25,126,709.32 |
| 其中:利息费用 | 2,137,754.89 | 401,349.43 | 1,931,970.93 | 1,434,811.58 |
| 其中:利息收入 | 13,434,876.18 | 6,330,596.67 | 30,854,753.16 | 23,427,040.88 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 2,544,678.15 | 1,211,109.72 | 5,727,685.2 | 4,777,667.41 |
| 加:投资收益 | 685,258.34 | 288,917.17 | 8,901,527.36 | 9,432,419.29 |
| 资产处置收益 | 9,711.62 | 2,631.37 | 487,729.6 | -8,437.75 |
| 资产减值损失(新) | 30,380.92 | 14,724.34 | -4,981,502.71 | -462.03 |
| 信用减值损失(新) | -4,158,749.99 | 975,687.08 | -26,123,890.31 | -26,829,720.57 |
| 其他收益 | 6,172,463.49 | 3,486,188.86 | 20,104,339.24 | 14,137,235.56 |
| 四、营业利润 | 190,409,736.77 | 98,055,121.45 | 417,426,251.86 | 306,392,696.26 |
| 加:营业外收入 | 278.67 | 277.55 | 331,418.07 | 302,688.56 |
| 减:营业外支出 | 3,731,188.7 | 2,163,980.03 | 6,837,119.47 | 5,877,936.45 |
| 五、利润总额 | 186,678,826.74 | 95,891,418.97 | 410,920,550.46 | 300,817,448.37 |
| 减:所得税费用 | 20,553,622.21 | 10,734,494.55 | 49,665,229.41 | 38,311,509.27 |
| 六、净利润 | 166,125,204.53 | 85,156,924.42 | 361,255,321.05 | 262,505,939.1 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 166,125,204.53 | 85,156,924.42 | 361,255,321.05 | 262,505,939.1 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 166,125,204.53 | 85,156,924.42 | 361,255,321.05 | 262,505,939.1 |
| 扣除非经常损益后的净利润 | 161,719,299.4 | 82,755,551.48 | 343,401,498.32 | 250,415,716.06 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.42 | 0.22 | 0.91 | 0.67 |
| (二)稀释每股收益 | 0.42 | 0.22 | 0.9 | 0.67 |
| 八、其他综合收益 | -1,650,907.61 | - | 125,146.33 | 106,770.02 |
| 归属于母公司股东的其他综合收益 | -1,650,907.61 | - | 125,146.33 | 106,770.02 |
| 九、综合收益总额 | 164,474,296.92 | 85,156,924.42 | 361,380,467.38 | 262,612,709.12 |
| 归属于母公司股东的综合收益总额 | 164,474,296.92 | 85,156,924.42 | 361,380,467.38 | 262,612,709.12 |
| 公告日期 | 2026-08-25 | 2026-04-28 | 2026-04-16 | 2025-10-25 |
| 审计意见(境内) | | | 标准无保留意见 | |